Lille Cedex

• Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit … Recruiting
  2024-510981-18-00 5 2024-12-12 Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is o
• Evaluation of the Safety and Efficacy of Metformin in Steinert's Disease: A Prospective, Multicenter, Randomized, Double Blind, Phase 3 Tria … Recruiting
  2023-507660-39-00 5 2024-12-03 Myotonic dystrophy type 1 (DM1)
• Antiplatelet therapy after successful percutaneous coronary intervention for chronically occluded coronary artery: A prospective, multicentr … Recruiting
  2023-508148-23-01 5 2024-12-02 chronically occluded coronary artery
• Short versus long antiplatelet therapy after TAVI Recruiting
  2023-508208-40-00 10 2024-11-21 All adult patients with successful transfemoral trans-aortic valve imp
• Multicentre randomised double-blind superiority trial with a roll-over phase to evaluate the efficacy of OM-89 vs placebo in reducing antibi … Recruiting
  2024-512595-35-00 5 2024-11-21 neurogenic bladder
• Acute non-severe osteomyelitis in children Recruiting
  2024-516744-26-00 4 2024-11-15 acute osteomyelitis of the child
• Hypertension induced by intravenous administration of norepinephrine to improve the prognosis of patients with neurological deterioration in … Recruiting
  2023-508704-37-00 5 2024-11-08 Stroke
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing … Recruiting
  2024-516242-19-00 5 2024-11-05 lupus nephritis
• Multicenter randomized, double-blind, placebo controlled trial evaluating the effect of a 30-week caffeine treatment on cognition in early-t … Recruiting
  2024-514099-41-00 5 2024-10-31 Alzheimer's disease
• Efficacy and Safety of Obinutuzumab versus Rituximab in childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome : à double-bli … Recruiting
  2024-514240-93-00 10 2024-10-31 Idiopathic nephrotic syndrome (INS)
• A Long-term Extension Study of Guselkumab in Pediatric Participants Recruiting
  2023-509560-16-00 5 2024-10-29 Juvenile psoriatic arthritis (jPsA)
• QUIDOSE. Randomized controlled trial testing the efficacy of hydroxychloroquine combined with low dose corticosteroid therapy in pulmonary s … Recruiting
  2024-516101-23-00 5 2024-10-28 Sarcoidosis
• study of pembrolizumab in classic or endemic Kaposi’s sarcoma Recruiting
  2024-514241-10-00 4 2024-10-22 Kaposi's sarcoma
• FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting
  2024-515300-39-00 4 2024-10-18 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
• Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi … Recruiting
  2023-509334-19-00 5 2024-10-17 gastro-enteropancreatic neuroendocrine tumors (GEP-NETs)
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• A multi-center randomized phase II study comparing corticosteroids alone versus corticosteroids and extracorporeal photopheresis as first-li … Recruiting
  2023-508614-41-00 4 2024-10-15 The study will be proposed to all adult patients receiving an allogene
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting
  2023-508539-30-00 4 2024-10-10 Refractory Focal Onset Epilepsy
• A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chron … Recruiting
  2023-508338-33-00 5 2024-10-01 Chronic Inflammatory Demyelinating Polyneuropathy
• Substudy 06D: Combination Therapies in 2L Advanced Gastroesophageal Adenocarcinoma Recruiting
  2023-509306-29-00 9 2024-09-26 Gastroesophageal cancer
• Substudy 06C: Combination Therapies in Gastroesophageal Adenocarcinoma Recruiting
  2023-509307-33-00 9 2024-09-26 Gastroesophageal cancer
• JAKAHDI - JAK inhibitors in acquired hemophagocytic syndrome in the ICU Recruiting
  2023-504513-77-00 4 2024-09-16 Adult patients older than 18 years. Patients admitted to the participa
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)

Showing 241–264 of 681 trials